Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab

Carrie Wagner, Sudha Visvanathan, Jürgen Braun, Désirée Van Der Heijde, Atulya (Atul) Deodhar, Benjamin Hsu, Michael Mack, Michael Elashoff, Robert D. Inman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: Identify serum biomarkers modulated by golimumab treatment and associated with clinical response in patients with ankylosing spondylitis (AS). Methods: Sera were collected at weeks 0, 4 and 14 from 100 patients with active AS in the GO-RAISE study. Patients were randomly assigned subcutaneous injections of placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks. Samples were tested for select inflammatory, bone and cartilage markers, and protein profiling was also performed. Results: Golimumab treatment resulted in significant decreases in several serum proteins at weeks 4 and 14 compared with placebo. Patients who achieved clinical response at week 14, as assessed by a ≥20% improvement in the Assessment in SpondyloArthitis international Society response criteria (ASAS 20), demonstrated a distinct biomarker profile with lower levels of acute phase reactants and inflammatory biomarkers compared with patients who did not. Notably, combinations of two or three biomarkers assessed at baseline were predictive of various clinical outcomes (ASAS 20, Bath ankylosing spondylitis disease activity index 50 or Bath ankylosing spondylitis functional index) using a logistic regression analysis, and the overall predictive values for these combined biomarkers were greater than observed for C-reactive protein (CRP) alone. Conclusion: Golimumab modulated acute phase reactants and inflammatory markers in patients with active AS. Specific combinations of biomarkers at baseline demonstrated a stronger prediction for clinical efficacy than CRP alone. These data provide insights into the mechanism of golimumab on inflammatory processes driving AS pathology, and may have utility in managing the treatment of patients with AS.

Original languageEnglish (US)
Pages (from-to)674-680
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume71
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Ankylosing Spondylitis
Biomarkers
Acute-Phase Proteins
C-Reactive Protein
Baths
Placebos
Cartilage
Pathology
Regression analysis
Subcutaneous Injections
golimumab
Logistics
Blood Proteins
Serum
Bone
Therapeutics
Logistic Models
Regression Analysis
Bone and Bones
Proteins

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. / Wagner, Carrie; Visvanathan, Sudha; Braun, Jürgen; Van Der Heijde, Désirée; Deodhar, Atulya (Atul); Hsu, Benjamin; Mack, Michael; Elashoff, Michael; Inman, Robert D.

In: Annals of the Rheumatic Diseases, Vol. 71, No. 5, 05.2012, p. 674-680.

Research output: Contribution to journalArticle

Wagner, C, Visvanathan, S, Braun, J, Van Der Heijde, D, Deodhar, AA, Hsu, B, Mack, M, Elashoff, M & Inman, RD 2012, 'Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab', Annals of the Rheumatic Diseases, vol. 71, no. 5, pp. 674-680. https://doi.org/10.1136/ard.2010.148890
Wagner, Carrie ; Visvanathan, Sudha ; Braun, Jürgen ; Van Der Heijde, Désirée ; Deodhar, Atulya (Atul) ; Hsu, Benjamin ; Mack, Michael ; Elashoff, Michael ; Inman, Robert D. / Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. In: Annals of the Rheumatic Diseases. 2012 ; Vol. 71, No. 5. pp. 674-680.
@article{3a1d9d8b402344b3857cf3de707c5a7c,
title = "Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab",
abstract = "Objective: Identify serum biomarkers modulated by golimumab treatment and associated with clinical response in patients with ankylosing spondylitis (AS). Methods: Sera were collected at weeks 0, 4 and 14 from 100 patients with active AS in the GO-RAISE study. Patients were randomly assigned subcutaneous injections of placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks. Samples were tested for select inflammatory, bone and cartilage markers, and protein profiling was also performed. Results: Golimumab treatment resulted in significant decreases in several serum proteins at weeks 4 and 14 compared with placebo. Patients who achieved clinical response at week 14, as assessed by a ≥20{\%} improvement in the Assessment in SpondyloArthitis international Society response criteria (ASAS 20), demonstrated a distinct biomarker profile with lower levels of acute phase reactants and inflammatory biomarkers compared with patients who did not. Notably, combinations of two or three biomarkers assessed at baseline were predictive of various clinical outcomes (ASAS 20, Bath ankylosing spondylitis disease activity index 50 or Bath ankylosing spondylitis functional index) using a logistic regression analysis, and the overall predictive values for these combined biomarkers were greater than observed for C-reactive protein (CRP) alone. Conclusion: Golimumab modulated acute phase reactants and inflammatory markers in patients with active AS. Specific combinations of biomarkers at baseline demonstrated a stronger prediction for clinical efficacy than CRP alone. These data provide insights into the mechanism of golimumab on inflammatory processes driving AS pathology, and may have utility in managing the treatment of patients with AS.",
author = "Carrie Wagner and Sudha Visvanathan and J{\"u}rgen Braun and {Van Der Heijde}, D{\'e}sir{\'e}e and Deodhar, {Atulya (Atul)} and Benjamin Hsu and Michael Mack and Michael Elashoff and Inman, {Robert D.}",
year = "2012",
month = "5",
doi = "10.1136/ard.2010.148890",
language = "English (US)",
volume = "71",
pages = "674--680",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab

AU - Wagner, Carrie

AU - Visvanathan, Sudha

AU - Braun, Jürgen

AU - Van Der Heijde, Désirée

AU - Deodhar, Atulya (Atul)

AU - Hsu, Benjamin

AU - Mack, Michael

AU - Elashoff, Michael

AU - Inman, Robert D.

PY - 2012/5

Y1 - 2012/5

N2 - Objective: Identify serum biomarkers modulated by golimumab treatment and associated with clinical response in patients with ankylosing spondylitis (AS). Methods: Sera were collected at weeks 0, 4 and 14 from 100 patients with active AS in the GO-RAISE study. Patients were randomly assigned subcutaneous injections of placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks. Samples were tested for select inflammatory, bone and cartilage markers, and protein profiling was also performed. Results: Golimumab treatment resulted in significant decreases in several serum proteins at weeks 4 and 14 compared with placebo. Patients who achieved clinical response at week 14, as assessed by a ≥20% improvement in the Assessment in SpondyloArthitis international Society response criteria (ASAS 20), demonstrated a distinct biomarker profile with lower levels of acute phase reactants and inflammatory biomarkers compared with patients who did not. Notably, combinations of two or three biomarkers assessed at baseline were predictive of various clinical outcomes (ASAS 20, Bath ankylosing spondylitis disease activity index 50 or Bath ankylosing spondylitis functional index) using a logistic regression analysis, and the overall predictive values for these combined biomarkers were greater than observed for C-reactive protein (CRP) alone. Conclusion: Golimumab modulated acute phase reactants and inflammatory markers in patients with active AS. Specific combinations of biomarkers at baseline demonstrated a stronger prediction for clinical efficacy than CRP alone. These data provide insights into the mechanism of golimumab on inflammatory processes driving AS pathology, and may have utility in managing the treatment of patients with AS.

AB - Objective: Identify serum biomarkers modulated by golimumab treatment and associated with clinical response in patients with ankylosing spondylitis (AS). Methods: Sera were collected at weeks 0, 4 and 14 from 100 patients with active AS in the GO-RAISE study. Patients were randomly assigned subcutaneous injections of placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks. Samples were tested for select inflammatory, bone and cartilage markers, and protein profiling was also performed. Results: Golimumab treatment resulted in significant decreases in several serum proteins at weeks 4 and 14 compared with placebo. Patients who achieved clinical response at week 14, as assessed by a ≥20% improvement in the Assessment in SpondyloArthitis international Society response criteria (ASAS 20), demonstrated a distinct biomarker profile with lower levels of acute phase reactants and inflammatory biomarkers compared with patients who did not. Notably, combinations of two or three biomarkers assessed at baseline were predictive of various clinical outcomes (ASAS 20, Bath ankylosing spondylitis disease activity index 50 or Bath ankylosing spondylitis functional index) using a logistic regression analysis, and the overall predictive values for these combined biomarkers were greater than observed for C-reactive protein (CRP) alone. Conclusion: Golimumab modulated acute phase reactants and inflammatory markers in patients with active AS. Specific combinations of biomarkers at baseline demonstrated a stronger prediction for clinical efficacy than CRP alone. These data provide insights into the mechanism of golimumab on inflammatory processes driving AS pathology, and may have utility in managing the treatment of patients with AS.

UR - http://www.scopus.com/inward/record.url?scp=84859490116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859490116&partnerID=8YFLogxK

U2 - 10.1136/ard.2010.148890

DO - 10.1136/ard.2010.148890

M3 - Article

C2 - 22039165

AN - SCOPUS:84859490116

VL - 71

SP - 674

EP - 680

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 5

ER -